Insider Buying: Prenetics Global (NASDAQ:PRE) CEO Acquires $364,752.63 in Stock

Prenetics Global Limited (NASDAQ:PRE) CEO Danny Sheng Wu Yeung bought 17,181 shares of Prenetics Global stock in a transaction on Monday, August 24th. The stock was acquired at an average cost of $21.23 per share, with a total value of $364,752.63. Following the acquisition, the chief executive officer owned 112,416 shares of the company’s stock, valued at $2,386,591.68. This trade represents a 18.04% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Danny Sheng Wu Yeung also recently made the following trade(s):

• On Thursday, August 20th, Danny Sheng Wu Yeung purchased 7,500 shares of Prenetics Global stock. The shares were bought at an average cost of $18.31 per share, for a total transaction of $137,325.00.

Prenetics Global Stock Up 10.9%

Shares of PRE opened at $25.78 on Thursday. The company has a 50-day simple moving average of $19.24 and a 200-day simple moving average of $18.98. The company has a market capitalization of $434.91 million, a PE ratio of -6.20 and a beta of 0.26. Prenetics Global Limited has a 52-week low of $7.27 and a 52-week high of $26.29.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The firm had revenue of $46.49 million for the quarter, compared to the consensus estimate of $49.85 million. On average, research analysts anticipate that Prenetics Global Limited will post -1.86 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new position in shares of Prenetics Global during the 3rd quarter worth approximately $65,000. UBS Group AG grew its holdings in Prenetics Global by 581.9% during the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after buying an additional 39,733 shares during the last quarter. Kingsview Wealth Management LLC purchased a new position in Prenetics Global during the fourth quarter worth $172,000. Goldman Sachs Group Inc. purchased a new position in Prenetics Global during the fourth quarter worth $665,000. Finally, T3 Companies LLC acquired a new position in shares of Prenetics Global in the fourth quarter worth $170,000. 25.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PRE has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Wall Street Zen raised Prenetics Global from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Benchmark lifted their price target on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Prenetics Global has a consensus rating of “Moderate Buy” and a consensus price target of $34.25.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.